A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

2024-511770-76-00 Protocol IBC-01-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 31 Oct 2023 · End 16 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol IBC-01-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 60
Countries 1
Sites 1

Alzheimer's disease

Key facts

Sponsor
Immunobrain Checkpoint Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
31 Oct 2023 → 16 Dec 2025
Decision date (initial)
2024-06-28
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511770-76-00
EudraCT number
2021-006580-19
WHO UTN
U1111-1303-6922
ClinicalTrials.gov
NCT05551741

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer's disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Immunobrain Checkpoint Ltd.

Sponsor organisation
Immunobrain Checkpoint Ltd.
Address
Weizmann Science Park, 3, Pinhas Sapir Street 3, Pinhas Sapir Street
City
Ness Ziona
Postcode
7414002
Country
Israel

Scientific contact point

Organisation
Immunobrain Checkpoint Ltd.
Contact name
Iris Tavor

Public contact point

Organisation
Immunobrain Checkpoint Ltd.
Contact name
Iris Tavor

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 1 1
Rest of world
Israel, United Kingdom
59

Investigational sites

Netherlands

1 site · Ended
Brain Research Center Amsterdam B.V.
Neurology, Cronenburg 2, 1081 GN, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2023-10-31 2025-10-21 2024-01-30 2025-01-21

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-19 Netherlands Acceptable
2024-06-28
2024-06-28
2 NON SUBSTANTIAL MODIFICATION NSM-2 2024-11-06 Netherlands Acceptable
2024-06-28
2024-11-06
3 NON SUBSTANTIAL MODIFICATION NSM-3 2025-01-28 Netherlands Acceptable
2024-06-28
2025-01-28
4 SUBSTANTIAL MODIFICATION SM-1 2025-04-28 Netherlands Acceptable
2025-05-21
2025-05-22